Section Arrow
Quote
PLYX.NASDAQ
- Polaryx Therapeutics Inc
Quotes are at least 15-min delayed:2026/05/14 11:36 EDT
Regular Hours
Last
 3.67
+0.305 (+9.06%)
Day High 
3.76 
Prev. Close
3.365 
1-M High
7.1 
Volume 
51.99K 
Bid
3.66
Ask
3.81
Day Low
3.18 
Open
3.49 
1-M Low
3 
Market Cap 
159.31M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.11 
20-SMA 4.81 
50-SMA 5.34 
52-W High 48.91 
52-W Low 2.201 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.19/-0.28
Enterprise Value
159.31M
Balance Sheet
Book Value Per Share
0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SANASana Biotechnology3.2------ 
ATYRaTyr Pharma Inc0.5295+0.1336+33.75%-- 
GTBPGT Biopharma0.40855+0.09585+30.65%-- 
GERNGeron Corp1.4102+0.0002+0.01%-- 
RGNXREGENXBIO6.3-3.74-37.25%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.